Singapore Institute for Clinical Sciences   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Singapore (2007)

Organization Overview

First Clinical Trial
2014
NCT03281083
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Singapore Institute for Clinical Sciences

Active Ingredients

Drugs in Phase 3 Trials (2)

dexmedetomidine (precedex) (1 trial)

sevoflurane (ultane) (1 trial)

Drugs in Phase 2 Trials (1)

levothyroxine (Synthroid) (1 trial)

Drugs in Other Trials (6)

autologous microbiome (1 trial)

b-cryptoxanthin (1 trial)

beef (1 trial)

beetroot juice (1 trial)

lamb (1 trial)

myoinositol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatty Liver (Phase 2)

Hernia (Phase 3)

Hernia, Inguinal (Phase 3)

Liver Diseases (Phase 2)

Neurodevelopmental Disorders (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 9